The thorough analysis of the few cases with membrane staining (n = 12) revealed that all but one carcinoma were wild type for the studied mutations (NRAS, BRAF or TERTp). These cases presented variable outcomes i.e. presence of distant metastases, number of RAI therapies, cumulative dose of RAI, the need of additional treatments, disease-free status and death (disease caused), that are apparently unrelated with the presence of NIS membrane expression (Table 3). Table 3Clinicopathological and molecular data of cases presenting NIS membrane staining.DiagnosisBRAFNRASTERTpLymph node metastasesDistant metastasesNumber of 131I therapiesCumulative dose (mCi)Aditional treatmentsOne year DFS*DFS*,#DeathsCase 1cPTCWTWTWTNoBone3457.5NoNoNoNoCase 2cPTCWTWTWTNoNo163NoYesYesNoCase 3cPTCWTWTWTYesNo34592 surgeriesNoNoNoCase 4fvPTCWTWTWTYesNo137NoYesYesNoCase 5fvPTCWTWTWTNoNo2382NoNoNoNoCase 6PDTCWTWTWTNoLung + bone57982 surgeriesYesNoNoCase 7cPTCWTWT124G>AYesNo4527U/INoNoNoCase 8sclPTCWTWTWTYesNo3400U/INoNoNoCase 9FTCWTWTWTNoNo1102U/IU/IYesNoCase 10cPTCWTWTWTYesU/IU/IU/IU/IU/IU/IU/ICase 11fvPTCWTWTWTU/IU/IU/IU/IU/IU/IU/IU/ICase 12cPTCWTWTWTYesU/IU/IU/IU/IU/IU/IU/I*DFS disease-free survival; #at the end of follow-up.sclPTC, sclerosing variant of PTC; U/I, unavailable information.